Lamellar Biomedical Limited (Lamellar), is an innovative biotechnology company, pioneering new approaches for the transfer of functional nucleic acids. The Company’s unique and versatile LAMELLASOME platform has been designed for the safe and effective delivery of nucleic acid based therapeutics. Lamellar believes that its LAMELLASOME™ technology will play a key role in realising the potential of mRNAs, siRNAs, DNA, miRs, plasmids and other nucleic acids in development offering the potential to revolutionise the treatment of many rare and intractable diseases.
LAMELLASOME formulations have been shown to be effective in delivering functional nucleic acids to a range of cell types including macrophages, human pulmonary fibroblasts and human dendritic cells. The technology has also been used for the in vivo delivery of functional nucleic acids
Lamellar is developing its own pipeline of nucleic acid based therapeutics, the most advanced of which target Idiopathic Pulmonary Fibrosis and Cystic Fibrosis.
Founded in 2007, Lamellar is backed by both institutional and private investors, including Invesco, Scottish Enterprise, Barwell Plc, TRI Capital and has multiple research collaborations with world renowned institutions and universities.